Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc
Uras Jodl Iris,
** = Publikationen gelistet in SCI/SSCI/Pubmed
2019
Zeitschriftenaufsatz
** Uras, IZ; Maurer, B; Nivarthi, H; Jodl, P; Kollmann, K; Prchal-Murphy, M; Milosevic Feenstra, JD; Zojer, M; Lagger, S; Grausenburger, R; Grabner, B; Holly, R; Kavirayani, A; Bock, C; Gisslinger, H [and 3 others]
(2019): CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks.
Blood. 2019; 133(15):1677-1690
2018
** Uras, IZ; Maurer, B; Nebenfuehr, S; Zojer, M; Valent, P; Sexl, V
(2018): Therapeutic Vulnerabilities in FLT3 -Mutant AML Unmasked by Palbociclib.
Int J Mol Sci. 2018; 19(12): 3987.
** Valent, P; Büsche, G; Theurl, I; Uras, IZ; Germing, U; Stauder, R; Sotlar, K; Füreder, W; Bettelheim, P; Pfeilstöcker, M; Oberbauer, R; Sperr, WR; Geissler, K; Schwaller, J; Moriggl, R [and 4 others]
(2018): Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts.
Haematologica. 2018; 103(10):1593-1603
2017
** Uras, IZ; Bellutti, F; Sexl, V
(2017): p27 in FLT3-driven acute myeloid leukemia: many roads lead to ruin.
Haematologica. 2017; 102(8):1299-1301
** Uras, IZ; Scheicher, RM; Kollmann, K; Glösmann, M; Prchal-Murphy, M; Tigan, AS; Fux, DA; Altamura, S; Neves, J; Muckenthaler, MU; Bennett, KL; Kubicek, S; Hinds, PW; von Lindern, M; Sexl, V
(2017): Cdk6 contributes to cytoskeletal stability in erythroid cells.
Haematologica. 2017; 102(6):995-1005
Kongressbeitrag in einer Zeitschrift
** Uras, I; Valent, P; Sexl, V
(2017): Targeted Combination Therapy With Cdk4/6 Inhibitor Palbociclib In AML.
22nd Congress of the European-Hematology-Association,
Madrid, SPAIN, Spain,
JUN 22-25, 2017.
Haematologica (102), S2 207-208.
2016
Zeitschriftenaufsatz
** Uras, IZ; Walter, GJ; Scheicher, R; Bellutti, F; Prchal-Murphy, M; Tigan, AS; Valent, P; Heidel, FH; Kubicek, S; Scholl, C; Fröhling, S; Sexl, V
(2016): Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.
Blood. 2016; 127(23):2890-2902
Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)
Bellutti, F; Uras, I; Prchal-Murphy, M; Tigan, A; Rodríguez-Díez, E; Quereda, V; Malumbres, M; Sexl, V (2016): Uncoupling CDK4/6 from INK4 inhibitors – Molecular consequences for leukemogenesis. -Cellular signalling and cancer therapy; MAI 27–31, 2016 ; Cavtat, CROATIA.
Bellutti, F; Uras, ZI; Prchal-Murphy, M; Tigan, AS; Rodríguez-Díez, E; Quereda, V; Malumbres, M; Sexl, V (2016): Uncoupling CDK4/6 from INK4 inhibitors – Molecular consequences for leukemogenesis. Hematological Malignancies: from Mechanisms to Therapy; MAR 9-12, 2016; Milano, ITALY. 2016.
2015
Tigan, A; Uras, I; Prchal-Murphy, M; Bago-Horvath, Z; Kudweis, P; Scheicher, R; Kollmann, K; Sexl, V (2015): Loss of CDK6 accelerates JUNB driven myeloproliferative disease and leukemia. -HEMID 2015 Meeting "Epigenetic regulation of hematopoiesis and leukemogenesis"; APR 21-22, 2015; Strassburg, FRANCE.
Uras, I; Walter, G; Bellutti, F; Prchal-Murphy, M; Scheicher, R; Tigan, A; Valent, P; Scholl, C; Fröhling, S; Sexl, V (2015): CDK6: a novel transciptional angel on the treatment of an agressive subtype of AML. -ESH International Conference on Cute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment; SEP 10-12, 2015; Budapest, HUNGARY.